Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Brem
Denny Brem, Munich DE
| Patent application number | Description | Published |
|---|---|---|
| 20090022077 | COMPUTING DEVICE, HARDWARE DATA TRANSFER UNIT, SOFTWARE CONTROL UNIT, AND METHOD FOR PERFORMING A DATA TRANSFER IN A COMPUTING DEVICE - A computing device includes a hardware data processing unit having at least one input buffer, a plurality of output buffers, a data transfer unit, and a software control unit, the data transfer unit configured to transfer data from the input buffer to the plurality of output buffers, and the software control unit configured to control the data transfer unit. | 01-22-2009 |
Franziska Brem, Zürich CH
| Patent application number | Description | Published |
|---|---|---|
| 20100035373 | Method for manufacturing a sensor device with a stress relief layer - A method for packaging a sensor device having a sensitive structure integrated on a semiconductor chip is provided. When molding the device package, an inward extending section of the mold maintains an access opening to the sensor. A buffer layer is arranged on the chip between the inward extending section and the sensitive structure. The buffer layer protects the sensitive structure from damage by the inward extending section and acts as a seal while casting the housing. The buffer layer also covers at least part of the semiconductor electronic components of the circuitry integrated onto the chip. By covering these components, mechanical stress, as it is e.g. caused by different thermal expansion coefficients of the packaging and the chip, can be reduced. | 02-11-2010 |
Franziska Brem, Zurich CH
| Patent application number | Description | Published |
|---|---|---|
| 20100035373 | Method for manufacturing a sensor device with a stress relief layer - A method for packaging a sensor device having a sensitive structure integrated on a semiconductor chip is provided. When molding the device package, an inward extending section of the mold maintains an access opening to the sensor. A buffer layer is arranged on the chip between the inward extending section and the sensitive structure. The buffer layer protects the sensitive structure from damage by the inward extending section and acts as a seal while casting the housing. The buffer layer also covers at least part of the semiconductor electronic components of the circuitry integrated onto the chip. By covering these components, mechanical stress, as it is e.g. caused by different thermal expansion coefficients of the packaging and the chip, can be reduced. | 02-11-2010 |
| 20100117185 | Temperature sensor with buffer layer - A temperature sensor with a bandgap circuit is provided. The bandgap circuit is covered by a buffer layer of photoresist. The device is packaged in a housing. By providing the buffer layer, mechanical stress in the bandgap circuit, as it is e.g. caused by different thermal expansion coefficients of the packaging and the chip, can be reduced. This improves the accuracy of the device. | 05-13-2010 |
Gottfried Brem, Hilgertshausen DE
| Patent application number | Description | Published |
|---|---|---|
| 20110186519 | PROCESS FOR MANUFACTURING A COMPOSITE SORBENT MATERIAL FOR CHORMATOGRAPHICAL SEPARATION OF BIOPOLYMERS - The present invention relates to a sorbent material for separation and purification of biopolymers, particularly nucleic acids, having a solid support substantially modified with a copolymer coating comprising aromatic monomers and crosslinking compounds and unsaturated esters or ethers preferably attached to the support via a vinylchlorsilane. The use of these materials for separation of nucleic acids, particularly a one-step isolation of DNA from lysates of different biological sources, is an object of the invention as well as a chromatographic column or cartridge at least partially filled with the sorbent material of the invention, a membrane-like device comprising the sorbent material of the invention, and a kit comprising the sorbent material of the invention in bulk or packed in chromatographic devices as well as other devices necessary for performing sample preparations. | 08-04-2011 |
Harold Brem, Bronx, NY US
| Patent application number | Description | Published |
|---|---|---|
| 20080234194 | GROWTH FACTOR MEDIATED COSMECEUTICALS AND USE THEREOF TO ENHANCE SKIN QUALITY - It has been discovered that vascular endothelial growth factor (“VEGF”) promotes migration of activated (but not differentiating) keratinocytes to skin. This growth factor specifically increases migration of keratinocytes of the “wounded skin” phenotype but does not have significant effects upon differentiated keratinocytes. It also increases collagen deposition and reduces wrinkles, enhances skin quality, and increases skin thickness to normal levels in individuals where skin has thinned due to age or disorder such as diabetes. It is particularly well suited for use as cosmeceuticals when applied in purified form and in known amounts. The data presented in the examples demonstrate efficacy and specificity of VEGF in enhancing migration of normal human keratinocytes as well as formation of new granulation tissue including collagen formation. VEGF induces keratinocyte and fibroblast migration, formation of new tissue, and not only induces deposition of collagen but improves alignment of the collagen fibers. Accordingly, this growth factor is highly suitable for use as a cosmeceutical, especially for skin resurfacing and reduction in wrinkles. | 09-25-2008 |
| 20080274079 | De novo synthesis of glucocorticoids in the epidermis and its uses and applications - The present invention relates to methods and compositions that control, i.e., antagonize/inhibit or agonize/stimulate, de novo glucocorticoid production in the skin. Such methods and compositions can be used for the prevention and/or treatment of a variety of skin conditions, including inflammation, acute wounds, chronic non-healing wounds, keloid, fibrotic or hypertrophic scars, and epithelial-derived cancer. | 11-06-2008 |
| 20090191156 | GM-CSF COSMECEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF - It has been discovered that granulocyte macrophage colony stimulating factor (“GM-CSF”) promotes migration of activated (but not differentiating) keratinocytes to wound sites. It was also discovered that GM-CSF increases the quantity and improves the quality of collagen. This growth factor specifically increases migration of keratinocytes of the “wound” phenotype but does not have significant effects upon differentiated keratinocytes. Examples demonstrate reversal of skin impairment in multiple animal models of diabetic skin imparment when provided in an effective amount over an effective time period. The examples also demonstrate the efficacy of the formulations in cosmetic applications. A preferred formulation is a sustained release formulation that delivers sufficient growth factor to the skin and the underlying tissue thereof to increase the rate of keratinocyte migration, as well as collagen deposition and fibroblast proliferation, in the skin to promote rejuvenation of skin injuries resistant to repair due to underlying disease, such as diabetes, or aging. | 07-30-2009 |
| 20090203006 | BIOLOGICAL MARKERS OF CHRONIC WOUND TISSUE AND METHODS OF USING FOR CRITERIA IN SURGICAL DEBRIDEMENT - The present invention relates to methods for identifying tissue sites in a chronic wound that are suitable for debridement and whether debridement procedure has been successful using particular biological markers of the cells within the tissue sites of the chronic wounds. | 08-13-2009 |
| 20100310517 | GROWTH FACTOR MEDIATED COSMECEUTICALS AND USE THEREOF TO ENHANCE SKIN QUALITY - It has been discovered that vascular endothelial growth factor (“VEGF”) promotes migration of activated (but not differentiating) keratinocytes to skin. This growth factor specifically increases migration of keratinocytes of the “wounded skin” phenotype but does not have significant effects upon differentiated keratinocytes. It also increases collagen deposition and reduces wrinkles, enhances skin quality, and increases skin thickness to normal levels in individuals where skin has thinned due to age or disorder such as diabetes. It is particularly well suited for use as cosmeceuticals when applied in purified form and in known amounts. The data presented in the examples demonstrate efficacy and specificity of VEGF in enhancing migration of normal human keratinocytes as well as formation of new granulation tissue including collagen formation. VEGF induces keratinocyte and fibroblast migration, formation of new tissue, and not only induces deposition of collagen but improves alignment of the collagen fibers. Accordingly, this growth factor is highly suitable for use as a cosmeceutical, especially for skin resurfacing and reduction in wrinkles. | 12-09-2010 |
| 20110190372 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS - Compositions and methods for antagonizing miRNAs that are overexpressed in chronic, non-healing wounds, as compared to healthy tissue, are disclosed. The miRNA antagonists are oligonucleotides that hybridize to selected pre-miRNA or mature miRNAs and prevent the miRNAs from binding to and downregulating their target mRNAs. Methods of using the miRNA antagonists to treat inflammatory disorders, including to promote healing of chronic, non-healing wounds and acute wounds are provided. | 08-04-2011 |
Henry Brem, Owings Mills, MD US
| Patent application number | Description | Published |
|---|---|---|
| 20080260834 | VITAMIN D3 ANALOG LOADED POLYMER FORMULATIONS FOR CANCER AND NEURODEGENERATIVE DISORDERS - Localized delivery of 1,25 D | 10-23-2008 |
| 20110313010 | COMBINATION OF LOCAL TEMOZOLOMIDE WITH LOCAL BCNU - The additive effect of combined intracranial carmustine (“BCNU”) with intracranial temozolomide (“TMZ”), and particularly in combination with radiation (“XRT”), in the treatment of two rat intracranial glioma models, the 9L gliosarcoma and the F98 glioma, demonstrates that local delivery of both drugs, especially in combination with radiation, is far more effective than delivery of either drug alone or one systemically and one locally, either with or without radiation. The triple therapy showed a significant improvement in survival when compared to controls (p=0.0004), local BCNU (p=0.0043), oral TMZ (p=0.0026), local TMZ (p=0.0105), and the combinations of either BCNU and XRT (p=0.0378) or oral TMZ and local BCNU (p=0.0154). | 12-22-2011 |
Nadine Brem, Muhlhausen-Rettigheim DE
| Patent application number | Description | Published |
|---|---|---|
| 20120071671 | CATALYST AND METHOD FOR PARTIALLY OXIDIZING HYDROCARBONS - The invention relates to a catalyst for partially oxidizing hydrocarbons in the gas phase, containing a multi-metal oxide of the general formula (I), AgaMObVcMdOe.f H2O (I), wherein M stands for at least one element selected from among Li, Na, K, Rb, Cs, Be, Mg, Ca, Sr, Ba, B, Al, Ga, In, Si, Sn, Pb, P, Sb, Bi, Y, Ti, Zr, Hf, V, Nb, Ta, Cr, W, Mn, Re, Fe, Ru, Os, Co, Rh, Ir, Ni, Pd, Pt, Cu, Au, Zn, Cd, La, Ce, Pr, Nd, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, Lu, and U, a has a value of 0.5 to 1.5, b has a value of 0.5 to 1.5, c has a value of 0.5 to 1.5, a+b+c has the value 3, d has a value of less than 1, e means a number that is determined by the valence and frequency of the elements other than oxygen in the formula (I), f has a value of 0 to 20, which multi-metal oxide exists in a crystal structure, the X-ray powder diffractogram of which is characterized by diffraction reflections at a minimum of 5 lattice distances selected from among d=4.53, 3.38, 3.32, 3.23, 2.88, 2.57, 2.39, 2.26, 1.83, 1.77 AA (+−0.04 AA). | 03-22-2012 |
Rachel F. Brem, Owings Mills, MD US
| Patent application number | Description | Published |
|---|---|---|
| 20120121510 | LOCALIZED THERAPY FOLLOWING BREAST CANCER SURGERY - Particles providing prolonged release of chemotherapy are injected or implanted into surgical sites in the breast following removal of cancerous tissue. In one embodiment, the particles are designed to not release formulation for approximately two to three weeks after surgery so as to not inhibit healing; in another embodiment particles are not administered until two to three weeks after surgery, and release immediately. The particles then release an effective amount of a chemotherapeutic such as a taxane to inhibit proliferation of any remaining cancer cells at or near the surgical site. This may also help prevent overproliferation leading to scarring with the surgical region. | 05-17-2012 |
William Brem, Muri CH
| Patent application number | Description | Published |
|---|---|---|
| 20110114212 | DEVICE FOR OPENING A CLOSED FLUID CONTAINER - An opening device for opening a closed fluid container comprises a housing having a first chamber ( | 05-19-2011 |
| 20110253806 | SPRAY HEAD AND SPRAYING DEVICE HAVING PRESSURIZED GAS LINE - A spraying device having a spray head for spraying at least one component comprises at least one substance component duct ( | 10-20-2011 |
| 20110278375 | DISCHARGE APPARATUS HAVING COMPRESSED GAS SUPPORT - A discharge apparatus for discharging a product having compressed gas support comprises a container ( | 11-17-2011 |